CDK4/6 Inhibitor SHR6390

Known as: SHR6390 
A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor SHR6390 selectively inhibits… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2017
0120002017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2007
2007
In adult vertebrates, most cells are not in the cell cycle at any one time. Physiological nonproliferation states encompass… (More)
  • figure 1
  • table I
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
We have investigated the regulation of cell-cycle entry in C. elegans, taking advantage of its largely invariant and completely… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2000
2000
The retinoblastoma family proteins pRB, p107, and p130 are phosphorylated and released from E2Fs in the late G(1) phase of the… (More)
Is this relevant?